Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma

Alon Harris, Christian P. Jonescu-Cuypers, Larry Kagemann, Elizabeth Anne Nowacki, Hanna Garzozi, Craig Cole, Bruce Martin

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

PURPOSE: Addition of dorzolamide to timolol in primary open-angle glaucoma shows augmented reduction of intraocular pressure. It is unknown as yet if addition of dorzolamide will alter hemodynamics. METHODS: Fifteen patients with primary open-angle glaucoma were placed on a medication-dependent 1-week to 4-week washout that included maintenance on timolol. After washout, baseline measurements were taken (timolol). They were studied after a month on timolol or dorzolamide-timolol (Cosopt®; Merck, Inc, Whitehouse Station, New Jersey), with the second drug preceded by another month of timolol maintenance and second baseline measurements. At each visit, visual function, intraocular pressure, and ocular hemodynamics were monitored, including indocyanine green and fluorescein angiography and color Doppler imaging. RESULTS: Cosopt® significantly reduced intraocular pressure (14.7 to 13.4 mm Hg, P < .05) and increased arteriovenous passage time (superior temporal artery) of fluorescein dye (2.13 to 1.76 seconds, P = .01) but had no effect on visual function. CONCLUSIONS: When compared with timolol in primary open-angle glaucoma, Cosopt® augments ocular tension reduction and reduces the amount of time required for blood to pass through the superior retinal vasculature.

Original languageEnglish
Pages (from-to)490-495
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume132
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Timolol
dorzolamide
Intraocular Pressure
Hemodynamics
Maintenance
Temporal Arteries
Indocyanine Green
Fluorescein Angiography
Primary Open Angle Glaucoma
dorzolamide-timolol combination
Fluorescein
Coloring Agents
Color
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. / Harris, Alon; Jonescu-Cuypers, Christian P.; Kagemann, Larry; Nowacki, Elizabeth Anne; Garzozi, Hanna; Cole, Craig; Martin, Bruce.

In: American Journal of Ophthalmology, Vol. 132, No. 4, 2001, p. 490-495.

Research output: Contribution to journalArticle

Harris, Alon ; Jonescu-Cuypers, Christian P. ; Kagemann, Larry ; Nowacki, Elizabeth Anne ; Garzozi, Hanna ; Cole, Craig ; Martin, Bruce. / Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. In: American Journal of Ophthalmology. 2001 ; Vol. 132, No. 4. pp. 490-495.
@article{21ec94e79134425d8e39bed50ee3b577,
title = "Effect of dorzolamide timolol combination versus timolol 0.5{\%} on ocular bloodflow in patients with primary open-angle glaucoma",
abstract = "PURPOSE: Addition of dorzolamide to timolol in primary open-angle glaucoma shows augmented reduction of intraocular pressure. It is unknown as yet if addition of dorzolamide will alter hemodynamics. METHODS: Fifteen patients with primary open-angle glaucoma were placed on a medication-dependent 1-week to 4-week washout that included maintenance on timolol. After washout, baseline measurements were taken (timolol). They were studied after a month on timolol or dorzolamide-timolol (Cosopt{\circledR}; Merck, Inc, Whitehouse Station, New Jersey), with the second drug preceded by another month of timolol maintenance and second baseline measurements. At each visit, visual function, intraocular pressure, and ocular hemodynamics were monitored, including indocyanine green and fluorescein angiography and color Doppler imaging. RESULTS: Cosopt{\circledR} significantly reduced intraocular pressure (14.7 to 13.4 mm Hg, P < .05) and increased arteriovenous passage time (superior temporal artery) of fluorescein dye (2.13 to 1.76 seconds, P = .01) but had no effect on visual function. CONCLUSIONS: When compared with timolol in primary open-angle glaucoma, Cosopt{\circledR} augments ocular tension reduction and reduces the amount of time required for blood to pass through the superior retinal vasculature.",
author = "Alon Harris and Jonescu-Cuypers, {Christian P.} and Larry Kagemann and Nowacki, {Elizabeth Anne} and Hanna Garzozi and Craig Cole and Bruce Martin",
year = "2001",
doi = "10.1016/S0002-9394(01)01158-8",
language = "English",
volume = "132",
pages = "490--495",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma

AU - Harris, Alon

AU - Jonescu-Cuypers, Christian P.

AU - Kagemann, Larry

AU - Nowacki, Elizabeth Anne

AU - Garzozi, Hanna

AU - Cole, Craig

AU - Martin, Bruce

PY - 2001

Y1 - 2001

N2 - PURPOSE: Addition of dorzolamide to timolol in primary open-angle glaucoma shows augmented reduction of intraocular pressure. It is unknown as yet if addition of dorzolamide will alter hemodynamics. METHODS: Fifteen patients with primary open-angle glaucoma were placed on a medication-dependent 1-week to 4-week washout that included maintenance on timolol. After washout, baseline measurements were taken (timolol). They were studied after a month on timolol or dorzolamide-timolol (Cosopt®; Merck, Inc, Whitehouse Station, New Jersey), with the second drug preceded by another month of timolol maintenance and second baseline measurements. At each visit, visual function, intraocular pressure, and ocular hemodynamics were monitored, including indocyanine green and fluorescein angiography and color Doppler imaging. RESULTS: Cosopt® significantly reduced intraocular pressure (14.7 to 13.4 mm Hg, P < .05) and increased arteriovenous passage time (superior temporal artery) of fluorescein dye (2.13 to 1.76 seconds, P = .01) but had no effect on visual function. CONCLUSIONS: When compared with timolol in primary open-angle glaucoma, Cosopt® augments ocular tension reduction and reduces the amount of time required for blood to pass through the superior retinal vasculature.

AB - PURPOSE: Addition of dorzolamide to timolol in primary open-angle glaucoma shows augmented reduction of intraocular pressure. It is unknown as yet if addition of dorzolamide will alter hemodynamics. METHODS: Fifteen patients with primary open-angle glaucoma were placed on a medication-dependent 1-week to 4-week washout that included maintenance on timolol. After washout, baseline measurements were taken (timolol). They were studied after a month on timolol or dorzolamide-timolol (Cosopt®; Merck, Inc, Whitehouse Station, New Jersey), with the second drug preceded by another month of timolol maintenance and second baseline measurements. At each visit, visual function, intraocular pressure, and ocular hemodynamics were monitored, including indocyanine green and fluorescein angiography and color Doppler imaging. RESULTS: Cosopt® significantly reduced intraocular pressure (14.7 to 13.4 mm Hg, P < .05) and increased arteriovenous passage time (superior temporal artery) of fluorescein dye (2.13 to 1.76 seconds, P = .01) but had no effect on visual function. CONCLUSIONS: When compared with timolol in primary open-angle glaucoma, Cosopt® augments ocular tension reduction and reduces the amount of time required for blood to pass through the superior retinal vasculature.

UR - http://www.scopus.com/inward/record.url?scp=0034806547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034806547&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(01)01158-8

DO - 10.1016/S0002-9394(01)01158-8

M3 - Article

C2 - 11589868

AN - SCOPUS:0034806547

VL - 132

SP - 490

EP - 495

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -